Edarbi Approval History
FDA Approved: Yes (First approved February 25, 2011)
Brand name: Edarbi
Generic name: azilsartan medoxomil
Dosage form: Tablets
Company: Takeda Pharmaceutical Company Limited
Treatment for: High Blood Pressure
Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) for the treatment of hypertension.
Development History and FDA Approval Process for Edarbi
|Feb 28, 2011||FDA Approves Edarbi to Treat High Blood Pressure|
|Apr 27, 2010||Takeda Submits New Drug Application for Azilsartan Medoxomil in the U.S., an Investigational Compound for the Treatment of Hypertension|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.